|
US7045313B1
(en)
|
1982-11-30 |
2006-05-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
|
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
|
US4751180A
(en)
|
1985-03-28 |
1988-06-14 |
Chiron Corporation |
Expression using fused genes providing for protein product
|
|
US4935233A
(en)
|
1985-12-02 |
1990-06-19 |
G. D. Searle And Company |
Covalently linked polypeptide cell modulators
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
US5443964A
(en)
|
1987-08-10 |
1995-08-22 |
Duke University |
Poxvirus insertion/expression vector
|
|
US5283173A
(en)
|
1990-01-24 |
1994-02-01 |
The Research Foundation Of State University Of New York |
System to detect protein-protein interactions
|
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
|
WO1992019266A1
(en)
|
1991-05-06 |
1992-11-12 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
US5262522A
(en)
|
1991-11-22 |
1993-11-16 |
Immunex Corporation |
Receptor for oncostatin M and leukemia inhibitory factor
|
|
WO1994029351A2
(en)
|
1993-06-16 |
1994-12-22 |
Celltech Limited |
Antibodies
|
|
US5457035A
(en)
|
1993-07-23 |
1995-10-10 |
Immunex Corporation |
Cytokine which is a ligand for OX40
|
|
US6361770B1
(en)
|
1994-09-23 |
2002-03-26 |
University Of British Columbia |
Method of enhancing expression of MHC class I molecules bearing endogenous peptides
|
|
JP3907698B2
(ja)
|
1994-10-03 |
2007-04-18 |
アメリカ合衆国 |
抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
BR9612752A
(pt)
|
1996-10-25 |
2000-01-18 |
Human Genome Sciences Inc |
Neutrocina
|
|
US5969102A
(en)
|
1997-03-03 |
1999-10-19 |
St. Jude Children's Research Hospital |
Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
|
|
EP0979281B1
(en)
|
1997-05-02 |
2005-07-20 |
Genentech, Inc. |
A method for making multispecific antibodies having heteromultimeric and common components
|
|
GB9801930D0
(en)
|
1998-01-29 |
1998-03-25 |
Univ London |
Mutant herpes simplex viruses and uses thereof
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
DE69937291T2
(de)
|
1998-04-02 |
2008-07-10 |
Genentech, Inc., South San Francisco |
Antikörpervarianten und fragmente davon
|
|
GB2337755B
(en)
|
1998-05-29 |
2003-10-29 |
Secr Defence |
Virus vaccine
|
|
DK2272859T3
(en)
|
1998-08-07 |
2015-01-19 |
Univ Washington |
Immunological herpes simplex virus antigens and methods for their use
|
|
US7833529B1
(en)
|
1999-01-07 |
2010-11-16 |
Zymogenetics, Inc. |
Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
|
|
US20060067933A1
(en)
|
1999-01-07 |
2006-03-30 |
Gross Jane A |
Soluble receptor BR43x2 and methods of using
|
|
DE60005135T3
(de)
|
1999-01-07 |
2015-04-09 |
Zymogenetics, Inc. |
Lösliche rezeptoren br43x2 und verfahren zu deren therapeutischen verwendung
|
|
BR0008758A
(pt)
|
1999-01-15 |
2001-12-04 |
Genentech Inc |
Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US20030095967A1
(en)
|
1999-01-25 |
2003-05-22 |
Mackay Fabienne |
BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
|
|
US20030022233A1
(en)
|
1999-04-30 |
2003-01-30 |
Raymond G. Goodwin |
Methods of use of the taci/taci-l interaction
|
|
DE60039766D1
(de)
|
1999-08-09 |
2008-09-18 |
Targeted Genetics Corp |
Terologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen
|
|
US7329728B1
(en)
|
1999-10-25 |
2008-02-12 |
The Scripps Research Institute |
Ligand activated transcriptional regulator proteins
|
|
PT1255558E
(pt)
|
2000-02-16 |
2006-11-30 |
Genentech Inc |
Anticorpos anti-april e células hibridoma
|
|
CA2404945C
(en)
|
2000-04-27 |
2010-02-09 |
Biogen, Inc. |
Taci as an anti-tumor agent
|
|
US20040013674A1
(en)
|
2001-04-27 |
2004-01-22 |
Christine Ambrose |
Taci as an anti-tumor agent
|
|
EP1746106A3
(en)
|
2000-04-27 |
2007-03-14 |
Biogen Idec MA Inc. |
Use of TACI as an anti-tumor agent
|
|
CA2408617A1
(en)
|
2000-05-12 |
2001-11-22 |
Amgen Inc. |
Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
|
|
WO2001096528A2
(en)
|
2000-06-15 |
2001-12-20 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
|
EP2275449B1
(en)
|
2000-06-16 |
2016-09-28 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to BLyS
|
|
US7220840B2
(en)
|
2000-06-16 |
2007-05-22 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator protein
|
|
US7879328B2
(en)
|
2000-06-16 |
2011-02-01 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator
|
|
JP2004513878A
(ja)
|
2000-06-23 |
2004-05-13 |
マキシジェン， インコーポレイテッド |
新規同時刺激分子
|
|
WO2002066516A2
(en)
|
2001-02-20 |
2002-08-29 |
Zymogenetics, Inc. |
Antibodies that bind both bcma and taci
|
|
DK1436003T3
(da)
|
2001-05-24 |
2010-03-15 |
Zymogenetics Inc |
TACI-immunoglobulin-fusionsproteiner
|
|
JP2004537290A
(ja)
|
2001-05-24 |
2004-12-16 |
ヒューマン ジノーム サイエンシーズ， インコーポレイテッド |
腫瘍壊死因子δ（ＡＰＲＩＬ）に対する抗体
|
|
KR20040019105A
(ko)
|
2001-08-03 |
2004-03-04 |
제넨테크, 인크. |
ＴＡＣＩｓ 및 ＢＲ3 폴리펩티드 및 이의 용도
|
|
EP1456347A4
(en)
|
2001-11-16 |
2006-08-02 |
Human Genome Sciences Inc |
ANTIBODIES BINDING TO BLYS ACCORDING TO AN IMMUNOSPECIFIC MODE
|
|
AU2002352913B2
(en)
|
2001-11-30 |
2008-05-29 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Peptide agonists of prostate-specific antigen, and uses therefor
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
AU2003256836A1
(en)
|
2002-07-25 |
2004-02-16 |
Genentech, Inc. |
Taci antibodies and uses thereof
|
|
DE60329116D1
(de)
|
2002-10-11 |
2009-10-15 |
Zymogenetics Inc |
Herstellung von homotrimeren fusionsproteinen
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
PT1572744E
(pt)
|
2002-12-16 |
2010-09-07 |
Genentech Inc |
Variantes de imunoglobulina e utilizações destas
|
|
AU2003299971A1
(en)
|
2002-12-30 |
2004-07-29 |
Amgen Inc. |
Combination therapy with co-stimulatory factors
|
|
EP2272868B1
(en)
|
2003-06-05 |
2015-03-04 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
|
US20050163775A1
(en)
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
|
MXPA06004301A
(es)
|
2003-10-20 |
2006-06-05 |
Biogen Idec Inc |
Regimenes terapeuticos para antagonistas del factor de activacion de celulas b.
|
|
WO2005063816A2
(en)
|
2003-12-19 |
2005-07-14 |
Genentech, Inc. |
Monovalent antibody fragments useful as therapeutics
|
|
BR122019012028B1
(pt)
|
2004-04-13 |
2023-09-26 |
F. Hoffmann-La Roche Ag |
Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição
|
|
BRPI0510674A
(pt)
|
2004-07-15 |
2007-12-26 |
Xencor Inc |
variantes fc otimizadas
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ｏｘ４０ｌ抗體
|
|
EP1810979B1
(en)
|
2004-09-22 |
2012-06-20 |
Kyowa Hakko Kirin Co., Ltd. |
STABILIZED HUMAN IgG4 ANTIBODIES
|
|
AU2005305182A1
(en)
|
2004-11-04 |
2006-05-18 |
Genentech, Inc. |
Polypeptides that bind BAFF and/or APRIL
|
|
EP1819823A2
(en)
|
2004-12-01 |
2007-08-22 |
Bayer Schering Pharma Aktiengesellschaft |
Generation of replication competent viruses for therapeutic use
|
|
KR20070107687A
(ko)
|
2004-12-31 |
2007-11-07 |
제넨테크, 인크. |
Ｂｒ３과 결합하는 폴리펩티드, 및 그의 용도
|
|
JP5620626B2
(ja)
|
2005-03-31 |
2014-11-05 |
中外製薬株式会社 |
会合制御によるポリペプチド製造方法
|
|
KR101411165B1
(ko)
|
2005-07-01 |
2014-06-25 |
메다렉스, 엘.엘.시. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
|
|
AU2006278227B2
(en)
|
2005-08-09 |
2011-10-20 |
Ares Trading S.A. |
Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
|
|
ZA200801354B
(en)
|
2005-08-09 |
2009-08-26 |
Ares Trading Sa |
Methods for treating B-cell malignancies using TACI-lg fusion molecule
|
|
AU2006281978A1
(en)
|
2005-08-12 |
2007-02-22 |
Garvan Institute Of Medical Research |
Phrophylactic and/or therapeutic method for treatment of autoimmune disease
|
|
JP2007103345A
(ja)
|
2005-09-07 |
2007-04-19 |
Toyota Motor Corp |
チューブ状固体高分子型燃料電池、及びチューブ状固体高分子型燃料電池の製造方法
|
|
US7655439B2
(en)
|
2005-09-09 |
2010-02-02 |
Zymogenetics, Inc. |
Trimerizing polypeptides
|
|
US9168286B2
(en)
|
2005-10-13 |
2015-10-27 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
|
EA015860B1
(ru)
|
2005-10-13 |
2011-12-30 |
Хьюман Дженом Сайенсиз, Инк. |
Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
|
|
US8202698B2
(en)
|
2005-11-08 |
2012-06-19 |
Biogen Idec Ma Inc. |
Methods of evaluating BAFF
|
|
EA015342B1
(ru)
*
|
2006-05-15 |
2011-06-30 |
Арес Трейдинг С.А. |
Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig
|
|
SG173337A1
(en)
|
2006-07-21 |
2011-08-29 |
California Inst Of Techn |
Targeted gene delivery for dendritic cell vaccination
|
|
BRPI0716139A2
(pt)
|
2006-08-28 |
2013-09-17 |
Ares Trading Sa |
processo para purificaÇço de proteÍnas de fusço fc
|
|
JP2010501622A
(ja)
|
2006-08-28 |
2010-01-21 |
アレス トレーディング ソシエテ アノニム |
Ｆｃ−融合タンパク質の精製法
|
|
ES2755386T5
(es)
|
2006-08-28 |
2023-04-05 |
Ares Trading Sa |
Proceso para la purificación de proteínas que contienen fragmentos Fc
|
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
|
US20100063257A1
(en)
|
2007-01-26 |
2010-03-11 |
Merck Serono Sa |
Purification of FC-TACI Fusion Proteins Using the Oilbody Technology
|
|
ES2422479T3
(es)
|
2007-03-27 |
2013-09-11 |
Zymogenetics Inc |
Combinación de inhibición de BLyS y micofenolato de mofetilo para tratamiento de enfermedades autoinmunitarias
|
|
DK2167038T3
(en)
*
|
2007-06-13 |
2018-08-06 |
Zymogenetics Inc |
USING TACI-IG FUSION PROTEIN AS ATACICEPT TO PREPARE A MEDICINE FOR TREATING LUPUS ERYTHEMATOSUS
|
|
CN101323643B
(zh)
|
2007-06-15 |
2010-12-01 |
烟台荣昌生物工程有限公司 |
优化的TACI-Fc融合蛋白
|
|
DE602008005596D1
(de)
|
2007-06-21 |
2011-04-28 |
Univ Muenchen Tech |
Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
|
|
EP2514762B1
(en)
|
2007-07-13 |
2015-04-08 |
The Johns Hopkins University |
B7-DC variants
|
|
WO2009052293A1
(en)
|
2007-10-16 |
2009-04-23 |
Zymogenetics, Inc. |
Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
|
|
JP2011500757A
(ja)
|
2007-10-22 |
2011-01-06 |
メルク セローノ ソシエテ アノニム |
Ｆｃ含有タンパク質の精製方法
|
|
CA2703545A1
(en)
|
2007-11-12 |
2009-05-22 |
Ares Trading S.A. |
Taci-immunoglobulin fusion proteins for treatment of optic neuritis
|
|
CN105168123B
(zh)
|
2007-11-12 |
2019-03-08 |
阿雷斯贸易股份有限公司 |
Taci-免疫球蛋白融合蛋白制剂
|
|
EP2219673A1
(en)
|
2007-11-12 |
2010-08-25 |
Ares Trading S.A. |
Taci-immunoglobulin fusion proteins for treatment of relapsing multiple sclerosis
|
|
RS56844B1
(sr)
|
2007-12-11 |
2018-04-30 |
Univ North Carolina Chapel Hill |
Retrovirusni vektori sa modifikovanim polipurinskim nizom
|
|
EP2283355A2
(en)
|
2008-04-25 |
2011-02-16 |
Zymogenetics, Inc. |
Levels of bcma protein expression on b cells and use in diagnostic methods
|
|
US8003335B2
(en)
|
2008-04-30 |
2011-08-23 |
Universite Paris-SUD11 |
Levels of APRIL in serum and use in diagnostic methods
|
|
SI2291657T1
(sl)
|
2008-05-01 |
2016-09-30 |
Zymogenetics, Inc. |
Nivoji blys/april heterotrimerjev v serumu in uporaba pri diagnostičnih postopkih
|
|
WO2010003766A2
(en)
|
2008-06-17 |
2010-01-14 |
Apogenix Gmbh |
Multimeric tnf receptors
|
|
CA2735006A1
(en)
|
2008-08-25 |
2010-03-11 |
Amplimmune, Inc. |
Pd-1 antagonists and methods of use thereof
|
|
WO2010077634A1
(en)
|
2008-12-09 |
2010-07-08 |
Genentech, Inc. |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
WO2010093993A2
(en)
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
|
CA2763439A1
(en)
|
2009-05-28 |
2010-12-02 |
Glaxo Group Limited |
Antigen-binding proteins
|
|
WO2011109280A1
(en)
*
|
2010-03-05 |
2011-09-09 |
Lerner Research Institute |
Methods and compositions to treat immune-mediated disorders
|
|
CN101851278B
(zh)
|
2010-05-26 |
2013-03-13 |
石药集团中奇制药技术（石家庄）有限公司 |
B细胞激活因子拮抗剂及其制备方法与用途
|
|
US20110311548A1
(en)
|
2010-06-18 |
2011-12-22 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to treat asthma and other allergic and inflammatory conditions of the respiratory system
|
|
JP6267512B2
(ja)
|
2010-09-10 |
2018-01-24 |
ティゲニクス、エセ、ア、ウＴｉＧｅｎｉｘ，Ｓ．Ａ．Ｕ． |
幹細胞培養培地および方法
|
|
CN102085368B
(zh)
|
2011-01-19 |
2013-06-12 |
烟台荣昌生物工程有限公司 |
优化的TACI-Fc融合蛋白用于制备治疗系统性红斑狼疮药物的应用
|
|
MX348071B
(es)
|
2011-03-16 |
2017-05-26 |
Amgen Inc |
Variantes de fc.
|
|
WO2012141984A1
(en)
|
2011-04-08 |
2012-10-18 |
Immune Design Corp. |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
|
ES2608835T3
(es)
|
2011-04-13 |
2017-04-17 |
Bristol-Myers Squibb Company |
Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
|
|
WO2012149364A1
(en)
|
2011-04-28 |
2012-11-01 |
Diamond Don J |
Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
|
|
WO2013041029A1
(en)
*
|
2011-09-23 |
2013-03-28 |
Igenimed Pharmaceuticals Inc. |
Novel soluble ctla4 variants
|
|
TWI476001B
(zh)
|
2011-12-26 |
2015-03-11 |
Ind Tech Res Inst |
三倍體Ｆｃ融合蛋白及其用途
|
|
CN107496932A
(zh)
|
2012-02-27 |
2017-12-22 |
阿穆尼克斯运营公司 |
Xten缀合组合物和制造其的方法
|
|
CN102585016B
(zh)
*
|
2012-03-06 |
2014-06-04 |
江苏健德生物药业有限公司 |
一种可同时抑制t、b淋巴细胞功能的免疫融合蛋白、其制备方法及其应用
|
|
EP2831095B1
(en)
|
2012-03-30 |
2018-11-28 |
Immune Design Corp. |
Lentiviral vector particles having improved transduction efficiency for cells expressing dc-sign
|
|
WO2013184912A2
(en)
|
2012-06-06 |
2013-12-12 |
Oncomed Pharmaceuticals, Inc. |
Binding agents that modulate the hippo pathway and uses thereof
|
|
CN103232542B
(zh)
*
|
2013-02-01 |
2015-05-13 |
殷勇 |
一种双靶标嵌合蛋白
|
|
US10183967B2
(en)
|
2013-02-12 |
2019-01-22 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
|
ES2870802T3
(es)
|
2013-02-12 |
2021-10-27 |
Bristol Myers Squibb Co |
Métodos de replegado de proteínas a elevado pH
|
|
MX2015011670A
(es)
|
2013-03-15 |
2016-03-31 |
Biogen Ma Inc |
Tratamiento y prevencion de lesion renal aguda usando anticuerpos anti-alfa v beta 5.
|
|
BR112016016416A2
(pt)
|
2014-01-15 |
2017-10-03 |
Hoffmann La Roche |
VARIANTES DE REGIÕES-"Fc" COM 'FcRn' MODIFICADAS E PROPRIEDADES DE LIGAÇÃO DE PROTEÍNA "A" MANTIDAS
|
|
US10562954B2
(en)
*
|
2014-05-12 |
2020-02-18 |
Shanghai Kanda Biotechnology Co., Ltd. |
Fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof
|
|
WO2015181343A2
(en)
|
2014-05-30 |
2015-12-03 |
Ventana Medical Systems, Inc. |
Multiplex assay for improved scoring of tumor tissues stained for pd-l1
|
|
KR20170032373A
(ko)
|
2014-07-15 |
2017-03-22 |
이뮨 디자인 코포레이션 |
Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법
|
|
WO2016023001A1
(en)
|
2014-08-08 |
2016-02-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Multispecific high affinity pd-1 agents and methods of use
|
|
NL2014108B1
(en)
|
2015-01-09 |
2016-09-30 |
Aduro Biotech Holdings Europe B V |
Altered april binding antibodies.
|
|
US11655452B2
(en)
|
2015-06-25 |
2023-05-23 |
Icell Gene Therapeutics Inc. |
Chimeric antigen receptors (CARs), compositions and methods of use thereof
|
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
CN116333138A
(zh)
|
2015-07-30 |
2023-06-27 |
宏观基因有限公司 |
Pd-1结合分子和其使用方法
|
|
HRP20231578T1
(hr)
|
2015-11-25 |
2024-03-15 |
Visterra, Inc. |
Molekule protutijela na april i njihove uporabe
|
|
TW202208440A
(zh)
*
|
2015-12-14 |
2022-03-01 |
美商宏觀基因股份有限公司 |
對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
|
|
US11698369B2
(en)
|
2016-01-12 |
2023-07-11 |
Oncotracker, Inc. |
Methods for monitoring immune status of a subject
|
|
KR102824067B1
(ko)
|
2016-04-15 |
2025-06-23 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Icos 리간드 변이체 면역조절 단백질 및 그의 용도
|
|
EP3443000B1
(en)
|
2016-04-15 |
2025-11-12 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
EP3452101A2
(en)
|
2016-05-04 |
2019-03-13 |
CureVac AG |
Rna encoding a therapeutic protein
|
|
WO2017201040A1
(en)
|
2016-05-16 |
2017-11-23 |
Berenson James Richard |
Improved methods for monitoring immune status of a subject
|
|
EP4353750A3
(en)
|
2016-06-24 |
2024-07-24 |
iCell Gene Therapeutics LLC |
Chimeric antigen receptors (cars), compositions and methods thereof
|
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
|
CN110088127A
(zh)
|
2016-07-28 |
2019-08-02 |
高山免疫科学股份有限公司 |
Cd155变体免疫调节蛋白及其用途
|
|
AU2017345764A1
(en)
|
2016-10-20 |
2019-05-02 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
CA3054068A1
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
CN110809581A
(zh)
|
2017-03-16 |
2020-02-18 |
高山免疫科学股份有限公司 |
Pd-l2变体免疫调节蛋白及其用途
|
|
LT3596116T
(lt)
|
2017-03-16 |
2023-11-10 |
Alpine Immune Sciences, Inc. |
Imunomoduliacinių baltymų pd-l1 variantai ir jų naudojimo būdai
|
|
AU2018289493B2
(en)
|
2017-06-20 |
2025-07-03 |
Dana-Farber Cancer Institute, Inc. |
Methods for modulating regulatory T cells, regulatory B cells, and immune responses using modulators of the APRIL-TACI interaction
|
|
WO2019046818A1
(en)
|
2017-09-01 |
2019-03-07 |
Dana-Farber Cancer Institute, Inc. |
SPECIFIC IMMUNOGENIC PEPTIDES OF BCMA AND TACI ANTIGENS FOR THE TREATMENT OF CANCER
|
|
KR102813968B1
(ko)
*
|
2017-10-10 |
2025-05-29 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Ctla-4 변이체 면역조절 단백질 및 이의 용도
|
|
MX2020004540A
(es)
|
2017-10-18 |
2020-08-03 |
Alpine Immune Sciences Inc |
Proteinas inmunomoduladoras de ligando icos variante y composiciones y metodos relacionados.
|
|
GB201720426D0
(en)
|
2017-12-07 |
2018-01-24 |
Hummingbird Bioscience Pte Ltd |
CD47 and BCMA antigen-binding molecules
|
|
EP3735417A1
(en)
|
2018-01-03 |
2020-11-11 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
WO2019169290A1
(en)
|
2018-03-02 |
2019-09-06 |
Allogene Therapeutics, Inc. |
Inducible chimeric cytokine receptors
|
|
US20210238295A1
(en)
|
2018-04-26 |
2021-08-05 |
University Of Virginia Patent Foundation |
Compositions and methods for treating abdominal aortic aneurysm
|
|
CN110522908A
(zh)
|
2018-05-25 |
2019-12-03 |
荣昌生物制药（烟台）有限公司 |
TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用
|
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
|
WO2020028572A2
(en)
|
2018-08-01 |
2020-02-06 |
Unum Therapeutics Inc. |
ANTIBODY-COUPLED T CELL RECEPTORS (ACTRs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF
|
|
WO2020047329A1
(en)
*
|
2018-08-29 |
2020-03-05 |
Shattuck Labs, Inc. |
Chimeric proteins comprising extracellular domains and uses thereof
|
|
CN113544144A
(zh)
|
2018-09-19 |
2021-10-22 |
高山免疫科学股份有限公司 |
变体cd80融合蛋白和相关构建体的方法和用途
|
|
MX2021005366A
(es)
|
2018-11-08 |
2021-09-10 |
Juno Therapeutics Inc |
Metodos y combinaciones para el tratamiento y modulacion de celulas t.
|
|
CN113727998A
(zh)
|
2018-11-30 |
2021-11-30 |
高山免疫科学股份有限公司 |
Cd86变体免疫调节蛋白及其用途
|
|
AU2020257238A1
(en)
|
2019-04-17 |
2021-12-02 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant ICOS Ligand (ICOSL) fusion proteins
|
|
CN114728040A
(zh)
|
2019-06-14 |
2022-07-08 |
科优基因公司 |
新型白介素-2变体及其双功能融合分子
|
|
AU2020346580A1
(en)
|
2019-09-13 |
2022-03-31 |
Kyowa Kirin Co., Ltd. |
DcR3 variant
|
|
KR102844733B1
(ko)
|
2019-12-10 |
2025-08-11 |
레메젠 코, 리미티드 |
약제학적 TACI-Fc 융합 단백질 제제
|
|
US20220002381A1
(en)
|
2019-12-24 |
2022-01-06 |
Remegen Co., Ltd. |
Taci-fc fusion proteins and uses thereof
|
|
CN115812077A
(zh)
|
2020-05-08 |
2023-03-17 |
高山免疫科学股份有限公司 |
April和baff抑制性免疫调节蛋白及其使用方法
|
|
PH12022553243A1
(en)
|
2020-06-02 |
2024-02-12 |
Ares Trading Sa |
Methods related to the treatment of iga nephropathy
|
|
WO2022236335A1
(en)
|
2021-05-07 |
2022-11-10 |
Alpine Immune Sciences, Inc. |
Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
|
|
CA3196569A1
(en)
|
2021-08-10 |
2023-02-16 |
Jianmin Fang |
Method for treating iga nephropathy with taci-fc fusion protein
|
|
EP4296287A4
(en)
|
2021-09-30 |
2025-01-15 |
RemeGen Co., Ltd. |
METHODS FOR TREATING SJÖGREN'S SYNDROME WITH TACI-FC FUSION PROTEIN
|
|
WO2023236967A1
(zh)
|
2022-06-08 |
2023-12-14 |
荣昌生物制药(烟台)股份有限公司 |
用TACI-Fc融合蛋白治疗重症肌无力的方法
|
|
EP4598557A2
(en)
|
2022-10-04 |
2025-08-13 |
Alpine Immune Sciences, Inc. |
Mutated taci-fc fusion proteins for use in the treatment of autoantibody-mediated diseases
|